Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Older Adult Age Cohorts in Phase 1 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 29, 2020-- Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials